{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T05:03:47Z","timestamp":1770440627488,"version":"3.49.0"},"reference-count":53,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Systemic <jats:styled-content style=\"fixed-case\">AL<\/jats:styled-content> amyloidosis is a plasma cell dyscrasia with a characteristic clinical phenotype caused by multi\u2010organ deposition of an amyloidogenic monoclonal protein. This condition poses a unique management challenge due to the complexity of the clinical presentation and the narrow therapeutic window of available therapies. Improved appreciation of the need for risk stratification, standardised use of sensitive laboratory testing for monitoring disease response, vigilant supportive care and the availability of newer agents with more favourable toxicity profiles have contributed to the improvement in treatment\u2010related mortality and overall survival seen over the past decade. Nonetheless, with respect to the optimal management approach, there is a paucity of high\u2010level clinical evidence due to the rarity of the disease, and enrolment in clinical trials is still the preferred approach where available. This review will summarise the <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>linical <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>ractice <jats:styled-content style=\"fixed-case\">G<\/jats:styled-content>uidelines on the Management of Systemic <jats:styled-content style=\"fixed-case\">L<\/jats:styled-content>ight <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>hain (<jats:styled-content style=\"fixed-case\">AL<\/jats:styled-content>) Amyloidosis recently prepared by the <jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>edical <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>cientific <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>dvisory <jats:styled-content style=\"fixed-case\">G<\/jats:styled-content>roup of the <jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>yeloma <jats:styled-content style=\"fixed-case\">F<\/jats:styled-content>oundation of <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>ustralia. It is hoped that these guidelines will assist clinicians in better understanding and optimising the management of this difficult disease.<\/jats:p>","DOI":"10.1111\/imj.12566","type":"journal-article","created":{"date-parts":[[2014,8,28]],"date-time":"2014-08-28T12:28:25Z","timestamp":1409228905000},"page":"371-382","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Management of systemic <scp>AL<\/scp> amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group"],"prefix":"10.1111","volume":"45","author":[{"given":"N.","family":"Weber","sequence":"first","affiliation":[{"name":"Clinical Haematology and Bone Marrow Transplant Unit Royal Brisbane and Women's Hospital  Brisbane Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Mollee","sequence":"additional","affiliation":[{"name":"Amyloidosis Centre Princess Alexandra Hospital  Brisbane Australia"},{"name":"School of Medicine University of Queensland  Brisbane Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Augustson","sequence":"additional","affiliation":[{"name":"Department of Haematology Sir Charles Gairdner Hospital  Perth Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Haematology Royal Prince Alfred Hospital  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Catley","sequence":"additional","affiliation":[{"name":"School of Medicine University of Queensland  Brisbane Australia"},{"name":"Department of Haematology Mater Public Hospital  Brisbane Australia"},{"name":"Mater Medical Research Institute  Brisbane Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Gibson","sequence":"additional","affiliation":[{"name":"Department of Haematology Royal Prince Alfred Hospital  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Department of Haematology Peter MacCallum Cancer Centre  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. J.","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Haematology Royal Prince Alfred Hospital  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Horvath","sequence":"additional","affiliation":[{"name":"Department of Haematology South Australia Pathology  Adelaide Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Jaksic","sequence":"additional","affiliation":[{"name":"Department of Haematology Queen Elizabeth Hospital  Adelaide Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Joshua","sequence":"additional","affiliation":[{"name":"Department of Haematology Royal Prince Alfred Hospital  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Quach","sequence":"additional","affiliation":[{"name":"Department of Haematology St Vincent's Hospital  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. W.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology and BMT Royal Melbourne Hospital  Melbourne Victoria Australia"},{"name":"Faculty of Medicine, Dentistry and Health Sciences University of Melbourne  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Spencer","sequence":"additional","affiliation":[{"name":"Department of Haematology The Alfred Hospital  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Szer","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology and BMT Royal Melbourne Hospital  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Talaulikar","sequence":"additional","affiliation":[{"name":"Department of Haematology Canberra Hospital  Canberra Australia"},{"name":"Australian National University  Canberra Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"To","sequence":"additional","affiliation":[{"name":"Department of Haematology South Australia Pathology  Adelaide Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Zannettino","sequence":"additional","affiliation":[{"name":"Department of Haematology South Australia Pathology  Adelaide Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. M.","family":"Prince","sequence":"additional","affiliation":[{"name":"Department of Haematology Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Faculty of Medicine, Dentistry and Health Sciences University of Melbourne  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.7.1817.1817"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.12288"},{"key":"e_1_2_9_4_1","unstructured":"The Oxford Levels of Evidence 2.Oxford centre for evidence\u2010based medicine. [cited 2014 Jan 6]. Available from URL:http:\/\/www.cebm.net\/index.aspx?o=5653"},{"key":"e_1_2_9_5_1","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases","volume":"32","author":"Kyle R","year":"1995","journal-title":"Semin Hematol"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709253371306"},{"key":"e_1_2_9_7_1","unstructured":"QuachH PrinceHM.Clinical practice guideline: multiple myeloma.[cited 2014 Jan 6]. Available from URL:http:\/\/www.myeloma.org.au"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.029"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-286567"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23141"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09494"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(85)90521-2"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704243361702"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2788"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07327.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070484"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-253237"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09080.x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390930"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-388462"},{"key":"e_1_2_9_21_1","doi-asserted-by":"crossref","first-page":"2966a","DOI":"10.1182\/blood.V120.21.2966.2966","article-title":"A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus cyclophosphamide, thalidomide and dexamethasone (CTD) in the treatment of Mayo cardiac stage III patients with AL amyloidosis","volume":"120","author":"Venner CP","year":"2012","journal-title":"Blood"},{"key":"e_1_2_9_22_1","unstructured":"PalladiniG FoliA MilaniP ObiciL LavatelliF NuvoloneM.Melphalan and dexamethasone (MDex) vs. bortezomib melphalan and dexamethasone (BMDex) in AL amyloidosis: a matched case control study.XIIIth International Symposium on Amyloidosis Abstract Book: University Medical Center Groningen.2012:204a."},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2003.n.005"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3231"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-035352"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-030544"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-032987"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-294405"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-396903"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-407791"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4276"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702005"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701684518"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12673"},{"key":"e_1_2_9_35_1","first-page":"715","article-title":"Therapy and management of systemic AL (primary) amyloidosis","volume":"136","author":"Palladini G","year":"2006","journal-title":"Swiss Med Wkly"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.524329"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-330738"},{"issue":"1","key":"e_1_2_9_38_1","first-page":"122","article-title":"High\u2010dose melphalan and autologous stem cell transplantation for AL amyloidosis: recent trends in treatment\u2010related mortality and 1\u2010year survival at a single institution","volume":"18","author":"Seldin DC","year":"2011","journal-title":"Amyloid"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.01.022"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.100"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.7614"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2922"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04433.x"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4385"},{"issue":"1","key":"e_1_2_9_45_1","first-page":"91","article-title":"Functional correlates of N\u2010terminal natriuretic peptide type B (NT\u2010proBNP) response to therapy in cardiac light chain (AL) amyloidosis","volume":"18","author":"Perlini S","year":"2011","journal-title":"Amyloid"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2013-0361"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21822"},{"key":"e_1_2_9_48_1","unstructured":"WechalekarAD GillmoreJD FoardD RanniganL LaneT PinneyJHet\u2009al.Evaluation of an early switch to second line chemotherapy in AL amyloidosis among patients who fail to achieve a very good partial response to frontline treatment.XIIIth International Symposium on Amyloidosis. Groningen The Netherlands: International Society of Amyloidosis2012."},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2512"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(03)00027-4"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.04.013"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2007.10.016"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2008.05.016"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1992.00400230061010"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fimj.12566","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.12566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:07:52Z","timestamp":1695571672000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.12566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1111\/imj.12566"],"URL":"https:\/\/doi.org\/10.1111\/imj.12566","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"2014-06-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-08-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}